Nakata Joan, Hirota Tatsuhiko, Umemura Harue, Nakagawa Tomoko, Kando Naoyuki, Futamura Masaki, Nakamura Yasunori, Ito Komei
Department of Allergy, Aichi Children's Health and Medical Center, Obu 474-8710, Japan.
Core Technology Laboratories, Asahi Group Holdings, Ltd., Sagamihara 252-0206, Japan.
Asia Pac Allergy. 2019 Apr 22;9(2):e18. doi: 10.5415/apallergy.2019.9.e18. eCollection 2019 Apr.
Atopic dermatitis (AD) in infants is often related to food allergies (FA). The beneficial effects of lactic acid bacteria towards allergic diseases have been reported, but there are few reports on their effect and preferable dosages on AD in young children with concomitant FA.
To examine additional effects of two different dose of paraprobiotic L-92 (L-92) on the clinical treatment in young children afflicted by AD with diagnosed or suspected FA.
Fifty-nine AD young children from 10 months to 3 years old, with FA or who had not started to ingest specific food(s) because of high specific IgE levels, were recruited and randomly allocated into L-92 group (daily intake of 20 mg L-92/day) and placebo group. Participants were given test sample with conventional treatment for AD over a 24-week period. The severity of eczema was evaluated using SCORing Atopic Dermatitis (SCORAD) index before intervention, and at 4, 12, and 24 weeks after intervention.
After 24 weeks of intervention, a significant decrease in SCORAD was observed only in the L-92 group when compared with the baseline values. Significant decreases in thymus and activation-regulated chemokine (TARC) and total IgE were also detected 24 weeks after intake in the L-92 group compared with the placebo group.
It was suggested that intake of sufficient amounts of L-92 works as an adjunctive treatment of young children afflicted by AD with diagnosed or suspected FA.
婴儿特应性皮炎（AD）常与食物过敏（FA）相关。已有报道称乳酸菌对过敏性疾病有益，但关于其对伴有FA的幼儿AD的作用及最佳剂量的报道较少。
研究两种不同剂量的副益生菌L-92（L-92）对已确诊或疑似患有FA的AD幼儿临床治疗的额外效果。
招募了59名10个月至3岁的AD幼儿，他们患有FA或因特异性IgE水平高而尚未开始摄入特定食物，将其随机分为L-92组（每日摄入20mg L-92）和安慰剂组。参与者在24周内接受AD常规治疗的同时服用测试样本。在干预前以及干预后4周、12周和24周，使用特应性皮炎评分（SCORAD）指数评估湿疹的严重程度。
干预24周后，与基线值相比，仅L-92组的SCORAD显著降低。与安慰剂组相比，L-92组在摄入24周后，胸腺和活化调节趋化因子（TARC）以及总IgE也显著降低。
提示摄入足够量的L-92可作为已确诊或疑似患有FA的AD幼儿的辅助治疗方法。
